- Home
- IMC vs GLUE Comparison
IMC vs GLUE Comparison
Compare IMC & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMC | GLUE |
|---|---|---|
| Founded | 2025 | 2019 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 2026 | 2021 |
Fundamental Metrics
Financial Performance| Metric | IMC | GLUE |
|---|---|---|
| Price | $7.27 | $10.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $28.00 |
| AVG Volume (30 Days) | 91.3K | ★ 1.1M |
| Earning Date | 11-03-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $123,672,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $72.42 |
| Revenue Growth | N/A | ★ 63.54 |
| 52 Week Low | $4.80 | $8.94 |
| 52 Week High | $11.84 | $25.77 |
Technical Indicators
Market Signals| Indicator | IMC | GLUE |
|---|---|---|
| Relative Strength Index (RSI) | 48.58 | 27.23 |
| Support Level | $6.37 | N/A |
| Resistance Level | $8.29 | $12.26 |
| Average True Range (ATR) | 1.02 | 0.59 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 14.90 | 18.03 |
Price Performance
Historical ComparisonAbout IMC IMC Rare Earths Ltd Ordinary Shares
IMC Rare Earths Ltd is a mineral exploration and development company engaged in the exploration, evaluation and development of minerals and metals in Brazil. Its main REE project is the Itarantim Project located in the States of Bahia and Minas Gerais, Brazil.
About GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).